Rein Therapeutics, Inc. (RNTX): who owns it and who trades it
As of Nov 16, 2026, RNTX insiders reported 5 purchases worth $74.7K in the last 12 months. The largest buyer was Rickenbach Josef H Von (Director), with $49.7K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Rein Therapeutics
From the latest filingsOverall: more buying than selling. Funds and insiders mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RNTX
59 funds and institutions reported RNTX shares worth $42.5M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Voss Capital, LP with 18.8%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Voss Capital, LP | 5.26M | 18.77% | $5.5M | +20% |
| Cable Car Capital, LP | 5.20M | 18.53% | $5.4M | +1137% |
| ADAR1 Capital Management, LLC | 4.50M | 16.05% | $4.7M | New |
| Vanguard Capital Management LLC | 3.38M | 12.05% | $3.5M | +238% |
| BIOS Capital Management, LP | 2.98M | 10.64% | $3.1M | +50% |
| Ikarian Capital, LLC | 2.95M | 10.52% | $3.1M | New |
| Great Point Partners LLC | 2.58M | 9.18% | $2.7M | New |
| Citadel Advisors LLC | 2.44M | 8.70% | $2.5M | New |
| Velan Capital Investment Management LP | 1.70M | 6.06% | $1.8M | New |
| Senvest Management, LLC | 1.23M | 4.39% | $1.3M | +433% |
| Prosight Management, LP | 1.10M | 3.92% | $1.1M | +167% |
| Bleichroeder LP | 1.00M | 3.57% | $1M | New |
| Boothbay Fund Management, LLC | 889,450 | 3.17% | $925K | New |
| Geode Capital Management, LLC | 733,139 | 2.61% | $763K | +113% |
| University of Texas/texas Am Investment Management Co | 511,610 | 1.82% | $532K | No change |
| Vanguard Fiduciary Trust Co | 382,515 | 1.36% | $398K | +148% |
| State Street Corp | 379,604 | 1.35% | $395K | +400% |
| Empery Asset Management, LP | 370,834 | 1.32% | $386K | New |
| Sigma Planning Corp | 353,677 | 1.26% | $368K | +1% |
| BlackRock, Inc. | 326,204 | 1.16% | $339K | +376% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RNTX insiders reported $74.7K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 27, 2026 | Rickenbach Josef H Von | Director | Purchase | 4,500 | $1.07 | $4.8K | Form 4 |
| May 26, 2026 | Rickenbach Josef H Von | Director | Purchase | 23,190 | $1.06 | $24.6K | Form 4 |
| May 22, 2026 | Rickenbach Josef H Von | Director | Purchase | 15,950 | $1.05 | $16.7K | Form 4 |
| May 21, 2026 | Rickenbach Josef H Von | Director | Purchase | 3,420 | $1.04 | $3.6K | Form 4 |
| Apr 30, 2026 | James Brian Windsor | Director | Purchase | 25,000 | $1.00 | $25K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Rickenbach Josef H Von | Director | $49.7K | – | May 27, 2026 |
| James Brian Windsor | See Remarks, Director | $25K | – | Apr 30, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RNTX short interest
Low short interest. 0.8% of RNTX shares are sold short: about 1 share in 122. Over the last 12 reports the number of shares short went up 67%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 706,730 RNTX shares were sold short, 0.8% of the shares outstanding, up 19.6% from the report before. At the average daily volume of 336,368 shares, buying them all back would take about 2.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 706,730 | 0.82% | +20% | 336,368 | 2.1 |
| Oct 15, 2026 | 590,758 | 0.68% | -9% | 531,547 | 1.1 |
| Sep 30, 2026 | 651,179 | 0.75% | -3% | 277,566 | 2.4 |
| Sep 15, 2026 | 670,748 | 0.78% | +4% | 475,577 | 1.4 |
| Aug 31, 2026 | 642,979 | 0.75% | -13% | 542,548 | 1.2 |
| Aug 14, 2026 | 735,370 | 0.85% | -16% | 334,873 | 2.2 |
| Jul 31, 2026 | 875,037 | 3.12% | -0% | 453,565 | 1.9 |
| Jul 15, 2026 | 878,618 | 3.13% | -2% | 350,380 | 2.5 |
| Jun 30, 2026 | 898,096 | 3.20% | +188% | 804,191 | 1.1 |
| Jun 15, 2026 | 312,225 | 1.11% | -19% | 497,880 | 1.0 |
| May 29, 2026 | 387,486 | 1.38% | -9% | 489,244 | 1.0 |
| May 15, 2026 | 424,338 | 1.51% | -49% | 2.26M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Rein Therapeutics company events
Rein Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, listing). The latest was on Sep 4, 2026.
- Sep 4, 2026AnnouncementShared information with investors. Filing
- Aug 27, 2026ListingRein Therapeutics, Inc. received a notice of delisting from the Nasdaq Stock Market, LLC. The Notice stated that the Company had fallen below compliance with respect to the continued listing standard set forth in Rule 5550(a)(1) of the Nasdaq Listing Rules because the closing bid price of the… Filing
- Jul 21, 2026VoteReported shareholder vote results. Filing
- May 4, 2026AgreementEntry into a Definitive Material Agreement. Filing
- Mar 2, 2026AgreementEntry into a Definitive Material Agreement. Filing
- Feb 19, 2026LeadershipManuel C. Alves Aivado, M.D., Ph.D., notified Rein Therapeutics, Inc. of his decision to resign as a member of the Board of Directors of the Company, effective immediately. Filing
- Jan 16, 2026AgreementEntry into a Definitive Material Agreement. Filing
- Dec 11, 2025AgreementEnded an important agreement. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Rein Therapeutics financials
Famous investors that hold RNTX
2 of the 50 well-known investors we track reported holding RNTX in their latest 13F filing. The largest position is Ken Griffin's, worth $2.1M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.57M | $2.1M | 0.0% | +5% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 15,083 | $12.1K | 0.0% | -21% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Rein Therapeutics, Inc. (RNTX) stock
Who owns the most RNTX stock?
The largest reported owner of Rein Therapeutics, Inc. (RNTX) is Voss Capital, LP, with 18.8% of the company. In total, 59 funds and institutions reported holding RNTX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are RNTX insiders buying or selling?
In the last 12 months, RNTX insiders reported 5 open-market purchases worth $74.7K and no sales. The latest trade was on May 27, 2026. See every trade.
What is the short interest in RNTX?
As of Oct 30, 2026, 706,730 RNTX shares were sold short, 0.8% of the shares outstanding, up 19.6% from the report before. At the average daily volume of 336,368 shares, buying them all back would take about 2.1 trading days (days to cover). See the history.
Which famous investors hold RNTX?
2 of the 50 well-known investors we track reported RNTX in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $2.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.